Outlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial Launch

Dow Jones

2024/12/14

By Sabela Ojea

Outlook Therapeutics said it would trim its workforce by 23% with the goal of extending its cash runway as long as possible and move forward with the commercial launch of Lytenava in the European Union and the U.K.

The biopharmaceutical company on Friday said that the layoffs follow an internal strategic review and would lead to annual savings of about $1.4 million. The company had cash and cash equivalents of $32 million as of June 30, down from $47.2 million as of March 31.

Lytenava is the subject of a centralized Marketing Authorization granted by the European Commission in the European Union and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency in the U.K. for the treatment of wet age-related macular degeneration.

Wet AMD happens when abnormal blood vessels grow in the back of the eye and damage the macula.

The company continues to believe in the potential of Lytenava and is dedicated to advancing its regulatory and commercial efforts, Interim Chief Executive Lawrence Kenyon said.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

December 13, 2024 16:54 ET (21:54 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2491158649"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2491158649\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2491158649?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-14 05:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491158649","market":"fut","top_or_hot":-1,"title":"Outlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial Launch","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Outlook <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it would trim its workforce by 23% with the goal of extending its cash runway as long as possible and move forward with the commercial launch of Lytenava in the European Union and the U.K. \n</p>\n<p>\n  The biopharmaceutical company on Friday said that the layoffs follow an internal strategic review and would lead to annual savings of about $1.4 million. The company had cash and cash equivalents of $32 million as of June 30, down from $47.2 million as of March 31. \n</p>\n<p>\n  Lytenava is the subject of a centralized Marketing Authorization granted by the European Commission in the European Union and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency in the U.K. for the treatment of wet age-related macular degeneration. \n</p>\n<p>\n  Wet AMD happens when abnormal blood vessels grow in the back of the eye and damage the macula. \n</p>\n<p>\n  The company continues to believe in the potential of Lytenava and is dedicated to advancing its regulatory and commercial efforts, Interim Chief Executive Lawrence Kenyon said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 13, 2024 16:54 ET (21:54 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Outlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOutlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-14 05:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Outlook <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it would trim its workforce by 23% with the goal of extending its cash runway as long as possible and move forward with the commercial launch of Lytenava in the European Union and the U.K. \n</p>\n<p>\n  The biopharmaceutical company on Friday said that the layoffs follow an internal strategic review and would lead to annual savings of about $1.4 million. The company had cash and cash equivalents of $32 million as of June 30, down from $47.2 million as of March 31. \n</p>\n<p>\n  Lytenava is the subject of a centralized Marketing Authorization granted by the European Commission in the European Union and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency in the U.K. for the treatment of wet age-related macular degeneration. \n</p>\n<p>\n  Wet AMD happens when abnormal blood vessels grow in the back of the eye and damage the macula. \n</p>\n<p>\n  The company continues to believe in the potential of Lytenava and is dedicated to advancing its regulatory and commercial efforts, Interim Chief Executive Lawrence Kenyon said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 13, 2024 16:54 ET (21:54 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OTLK","symbol_name":"Outlook Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2491158649","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491158649","pubTimestamp":1734126840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Outlook Therapeutics said it would trim its workforce by 23% with the goal of extending its cash runway as long as possible and move forward with the commercial launch of Lytenava in the European Union and the U.K.The biopharmaceutical company on Friday said that the layoffs follow an internal strategic review and would lead to annual savings of about $1.4 million. The company had cash and cash equivalents of $32 million as of June 30, down from $47.2 million as of March 31.Lytenava is the subject of a centralized Marketing Authorization granted by the European Commission in the European Union and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency in the U.K. for the treatment of wet age-related macular degeneration.Wet AMD happens when abnormal blood vessels grow in the back of the eye and damage the macula.The company continues to believe in the potential of Lytenava and is dedicated to advancing its regulatory and commercial efforts, Interim C","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OTLK":"Outlook Therapeutics, Inc.","BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"Outlook Therapeutics将裁员23%以推动Lytenava的商业上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OTLK":0.9,"LENZ":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Outlook Therapeutics said it would trim its workforce by 23% with the goal of extending its cash runway as long as possible and move forward with the commercial launch of Lytenava in the European Union and the U.K. \n\n\n  The biopharmaceutical company on Friday said that the layoffs follow an internal strategic review and would lead to annual savings of about $1.4 million. The company had cash and cash equivalents of $32 million as of June 30, down from $47.2 million as of March 31. \n\n\n  Lytenava is the subject of a centralized Marketing Authorization granted by the European Commission in the European Union and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency in the U.K. for the treatment of wet age-related macular degeneration. \n\n\n  Wet AMD happens when abnormal blood vessels grow in the back of the eye and damage the macula. \n\n\n  The company continues to believe in the potential of Lytenava and is dedicated to advancing its regulatory and commercial efforts, Interim Chief Executive Lawrence Kenyon said. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 13, 2024 16:54 ET (21:54 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}